Skip to content

Comparison of Focal Cryoablation vs. Radiofrequency Cardioneuroablation for Bradyarrhythmias

Prospective Non-Randomized Comparison of Point-by-Point Cryoablation Using Freezor™ Xtra Versus Radiofrequency Ablation Using TactiFlex™ SE of Parasympathetic Ganglia (Cardioneuroablation) in Patients With Vagally-Mediated Bradyarrhythmias

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07671898
Acronym
CRYO-CNA vs RF
Enrollment
60
Registered
2026-06-26
Start date
2024-09-01
Completion date
2028-12-25
Last updated
2026-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrioventricular Block, Bradycardia, Sick Sinus Syndrome, Syncope, Vasovagal

Keywords

Cardioneuroablation,, Cryoablation, Radiofrequency Ablation, Ganglionated Plexi, Parasympathetic Nervous System, Bradyarrhythmias, Functional Bradycardia, Vasovagal Syncope, Sick Sinus Syndrome, Atrioventricular Block

Brief summary

Bradyarrhythmias are conditions where the heart beats too slowly, causing symptoms like dizziness, fainting, and fatigue. In some patients, these slow heart rhythms are caused by overactivity of the vagus nerve (the part of the nervous system that slows the heart down). Cardioneuroablation (CNA) is a catheter-based procedure that targets and reduces the effect of these overactive nerves on the heart. It is an alternative to permanent pacemaker implantation, especially for younger patients. Traditionally, CNA is performed using radiofrequency (RF) energy to create small burns in specific areas of the heart. This study investigates whether focal cryoablation (freezing technology using the Freezor™ Xtra catheter) is as safe and effective as standard RF ablation for CNA. This is a prospective, non-randomized study. Participants will receive either RF ablation (N=30) or cryoablation (N=30). The study will evaluate the recurrence of slow heart rhythms and fainting episodes, as well as any complications, over 12 months of follow-up.

Detailed description

Background and Rationale Cardioneuroablation is an emerging treatment for vagally-mediated bradyarrhythmias, including symptomatic sinus bradycardia, atrioventricular blocks, and vasovagal syncope with a cardioinhibitory component . The procedure targets ganglionated plexi located in the epicardial fat and myocardium, which contain parasympathetic nerve endings. While radiofrequency (RF) energy is the standard modality for CNA, epicardial fat may limit RF lesion formation when fat thickness exceeds 3 mm. Cryoablation, by contrast, uniformly cools tissue without energy dissipation in fat, potentially offering more consistent ganglion ablation. To date, no clinical study has compared focal cryoablation versus RF ablation specifically for cardioneuroablation. Objectives Primary: To compare the efficacy of focal cryoablation versus RF ablation for cardioneuroablation in preventing bradyarrhythmia recurrence. Secondary: To compare the safety profile of both techniques, including periprocedural complications and inappropriate sinus tachycardia. Study Design This is a prospective, non-randomized, parallel-group study conducted at a single center (Cardiology Research Institute, Tomsk NRMC). Eligible patients aged 18-60 years with symptomatic vagally-mediated bradyarrhythmias (confirmed by positive atropine test and/or EP study) are assigned non-randomly to either: Group 1 (RF-CNA, N=30): Radiofrequency ablation using TactiFlex™ SE catheter (Abbott), power 45W, target AI 45, with irrigation Group 2 (Cryo-CNA, N=30): Focal cryoablation using Freezor™ Xtra 6mm catheter (Medtronic), target temperature -75°C, 240 seconds per application Procedures All procedures are performed under intravenous sedation. After establishing venous access, a 3D electroanatomical map of the right atrium is created using the EnSite™ X system with HD Grid mapping catheter. Ganglionated plexi are identified using spectral analysis (OTNF algorithm) and anatomical landmarks (RAGP and IRGP). Ablation is applied at identified sites. Intraprocedural endpoints include: Reduction of SNRT \<1500 ms and cSNRT \<525 ms Wenckebach point ≥140 bpm AV node ERP \>300 ms Absence of bradycardic response to phenylephrine (\<10% heart rate reduction) Follow-up Patients are followed at 6 and 12 months post-procedure with clinical assessment, 12-lead ECG, and 24-hour Holter monitoring. Statistical Considerations The planned sample size is 60 patients (30 per group). Quantitative variables will be presented as mean±SD or median \[Q1;Q3\]. Paired t-test or Wilcoxon test will be used for pre-post comparisons. Between-group comparisons will use Mann-Whitney U test. Statistical significance set at p\<0.05.

Interventions

Focal cryoablation of right atrial ganglionated plexi using Freezor™ Xtra 6mm catheter (Medtronic) at -75°C for 240 seconds per application. 3-5 applications per GP zone. Positioned by fluoroscopy and impedance-based tracking in EnSite™ X system.

PROCEDURERadiofrequency Catheter Ablation

Radiofrequency ablation of right atrial ganglionated plexi using TactiFlex™ SE catheter (Abbott) with power up to 45W, temperature 50°C, target AI 45, with irrigation. 3-5 applications per GP zone. Guided by EnSite™ X mapping system and spectral analysis (OTNF).

Sponsors

Tomsk National Research Medical Center of the Russian Academy of Sciences
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Age 18 to 60 years; * Symptomatic bradycardia (sinus bradycardia or bradycardia due to atrioventricular block, including transient); * Severe asymptomatic sinus bradycardia (heart rate less than 30 beats per minute); * Transient second- or third-degree atrioventricular block; * Persistent second-degree atrioventricular block; * Rhythm pauses greater than 6 seconds; * Recurrent syncope or presyncope with documented association with bradycardia (without trauma); * Positive response to atropine (heart rate increase ≥25% from baseline or \>90 beats per minute) OR positive response to exercise (heart rate increase ≥25% from baseline or \>90 beats per minute, OR conversion of second- or third-degree atrioventricular block to first-degree block or complete normalization of atrioventricular conduction during sinus rhythm);

Exclusion criteria

* Chronic antiarrhythmic drug therapy (ongoing); * Presence of implanted pacemaker, cardiac resynchronization therapy device, or implantable cardioverter-defibrillator; * Bradyarrhythmia secondary to medications; * Bradyarrhythmia secondary to electrolyte imbalance (hyperkalemia); * Bradyarrhythmia secondary to hypothyroidism; * Bradyarrhythmia secondary to obstructive sleep apnea syndrome; * Absence of response to pharmacological denervation (no heart rate increase after atropine administration up to maximum dose of 0.2 mg/kg); * Clinically significant coronary artery disease; * Post-myocardial infarction cardiosclerosis; * Hemodynamically significant congenital heart disease (including surgically corrected); * Stable ventricular tachycardia in the setting of bradycardia; * History of stroke or transient ischemic attack; * Prior open-heart surgery; * Prior catheter-based coronary artery intervention or percutaneous coronary intervention; * Pregnancy or breastfeeding; Age less than 18 years Age greater than 60 years

Design outcomes

Primary

MeasureTime frameDescription
Recurrence of Bradyarrhythmia or Syncope12 monthsDocumented recurrence of symptomatic bradyarrhythmia (sinus bradycardia \<40 bpm, pause \>3 sec, AV block) or syncope confirmed by ECG or Holter

Secondary

MeasureTime frameDescription
Pericardial Effusion or HemopericardiumPeriprocedural (7 days)Pericardial effusion or hemopericardium requiring intervention, confirmed by echocardiography
Inappropriate Sinus Tachycardia12 monthsSustained sinus tachycardia \>100 bpm without cause, requiring beta-blocker therapy
Vascular Access ComplicationsPeriprocedural (7 days)Hematoma, pseudoaneurysm, or AV fistula requiring treatment, confirmed by ultrasound
Change in Minimum Heart RateBaseline to 6 monthsAbsolute change in minimum heart rate (bpm) on 24-hour Holter from baseline to 6 months
Change in Maximum Heart RateBaseline to 6 monthsAbsolute change in maximum heart rate (bpm) on 24-hour Holter from baseline to 6 months
Change in Electrophysiological ParametersIntraproceduralNormalization of cSNRT \<525 ms, Wenckebach point ≥140 bpm, AV-ERP \>300 ms
Change in Mean Heart RateBaseline to 6 monthsAbsolute change in minimum heart rate (bpm) on 24-hour Holter from baseline to 6 months

Countries

Russia

Contacts

CONTACTRoman E Batalov, MD, PhD
romancer@rambler.ru+73822558401

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 27, 2026